Keros Therapeutics (NASDAQ:KROS – Get Rating) announced its earnings results on Thursday. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.14) by ($0.12), Briefing.com reports. During the same quarter in the prior year, the business posted ($1.01) earnings per share. Keros Therapeutics Trading Down 3.9 % Keros Therapeutics […]
Keros Therapeutics (NASDAQ:KROS – Get Rating) released its quarterly earnings results on Thursday. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.14) by ($0.12), Briefing.com reports. During the same period in the prior year, the firm posted ($1.01) earnings per share. Keros Therapeutics Trading Down 3.5 % Shares of Keros […]
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) have been given a consensus rating of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) insider Jennifer Lachey sold 7,950 shares of the firm’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $60.00, for a total value of $477,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through […]
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) gapped up prior to trading on Thursday . The stock had previously closed at $63.27, but opened at $66.75. Keros Therapeutics shares last traded at $66.95, with a volume of 22 shares changing hands. Several research firms recently issued reports on KROS. HC Wainwright restated a […]